Results from a questionnaire-based study indicated an association between a history of abuse and increased sensory hypersensitivity symptoms among migraineurs.
A history of abuse is associated with greater migraine-related sensory hypersensitivity symptoms according to new research. The abstract will be presented at the American Academy of Neurology’s 73rd Annual Meeting, being held virtually between April 17-22, 2021.
Previous research has shown psychiatric comorbidities such as anxiety and depression are common among migraineurs. In addition, “prior studies have established an association between abuse and development of migraine and suggested this is attenuated after controlling for depression,” the researchers wrote, but limited research is available investigating abuse and individual migraine symptoms.
Notably, one 2020 study concluded the direct effect of childhood trauma on migraine is outweighed by the mediation effect of adulthood attachment. Individuals exposed to childhood trauma tend to exhibit insecure attachment patterns and are more prone to chronic and pain-related conditions, such as migraine.
Because individuals with high-attachment anxiety are prone to experience many interpersonal interactions as a source of distress, the researchers hypothesized being daily under stress may be a factor in the onset of migraine, triggering some attacks.
In the current study, researchers sought to assess the associations between a history of emotion, physical, and sexual abuse with severity of hypersensitivity symptoms in migraineurs, by having over 1000 adult migraineurs fill out multiple questionnaires.
A total of 1020 participants from the American Registry for Migraine Research completed the Generalized Anxiety Disorder-7, Patient Health Questionnaire-2 for depression, Photosensitivity Assessment Questionnaire, Hyperacusis Questionnaire, and Allodynia Symptom Checklist.
Thirty Six percent of patients self-reported a history of abuse (n = 365) while T-tests compared scores between cohorts with and without a history of abuse. Analyses revealed “abuse was associated with greater headache frequency (P = .019), anxiety (P <.001), depression (P <.001), photophobia (P <.001), hyperacusis (P <.001), ictal allodynia (P <.001), and interictal allodynia (P = .001).”
Analyses adjusted for age, gender, and headache frequency showed:
Future research into the pathophysiological mechanisms underlying the associations seen between abuse, psychiatric comorbidities, and migraine symptoms is needed, the researchers wrote. More studies “could lead to interventions that reduce the negative impact of abuse on the expressions and severity of migraine symptoms,” they concluded.
Reference:
Trivedi M, Dumkrieger G, Chong C, Dodick D, Schwedt T. Impact of abuse on migraine symptoms and comorbidity: results from the American registry for migraine research (ARMR). Presented at American Academy of Neurology 73rd Annual Meeting; April 17-22, 2021; Virtual. Accessed April 12, 2021. https://index.mirasmart.com/AAN2021/PDFfiles/AAN2021-002187.html
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen